Aerpio Pharmaceuticals (United States)

Recent papers from Aerpio Pharmaceuticals (United States)

1. VE-PTP controls a fluid shear stress set point that governs cell morphological responses through Tie-2Frontiers in Cell and Developmental Biology · 2025
2. Predicting Progression to Vision-Threatening Complications in Diabetic RetinopathyOphthalmology Science · 2025
3. Inhibition of VE-PTP rejuvenates Schlemm’s canal in aged mice and acts via Tie2PLoS ONE · 2025
4. Shear stress control of vascular leaks and atheromas through Tie2 activation by VE‐PTP sequestrationEMBO Molecular Medicine · 2023
5. Tie2 Activation via VE-PTP Inhibition With Razuprotafib as an Adjunct to Latanoprost in Patients With Open Angle Glaucoma or Ocular HypertensionTranslational Vision Science & Technology · 2022
6. Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19JCI Insight · 2021
7. Oxidative metabolism of razuprotafib (AKB-9778), a sulfamic acid phosphatase inhibitor, in human microsomes and recombinant human CYP2C8 enzymeXenobiotica · 2021
8. Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-192021
9. A Small Molecule Inhibitor of VE-PTP Activates Tie2 in Schlemm's Canal Increasing Outflow Facility and Reducing Intraocular PressureInvestigative Ophthalmology & Visual Science · 2020
10. Enhancing Risk Assessment in Patients with Diabetic Retinopathy by Combining Measures of Retinal Function and StructureTranslational Vision Science & Technology · 2020
11. VE-PTP inhibition elicits eNOS phosphorylation to blunt endothelial dysfunction and hypertension in diabetesCardiovascular Research · 2020
12. Vascular Endothelial Receptor Tyrosine Phosphatase: Identification of Novel Substrates Related to Junctions and a Ternary Complex with EPHB4 and TIE2*[S]Molecular & Cellular Proteomics · 2019
13. Ageing skin: oestrogen receptor β agonists offer an approach to change the outcomeExperimental Dermatology · 2011
14. Emerging evidence of the health benefits of S-equol, an estrogen receptor β agonistNutrition Reviews · 2011
15. Single-dose and steady-state pharmacokinetic studies of S-equol, a potent nonhormonal, estrogen receptor β-agonist being developed for the treatment of menopausal symptomsMenopause The Journal of The North American Menopause Society · 2010